TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells

Cancer Gene Therapy

Volumn 9, Issue 4, 2002, Pages 372-381

  Beltinger, Christian ^a   Fulda, Simone ^a   Walczak, Henning ^b   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bystander effect; Neuroblastoma; Suicide gene therapy; TRAIL

Indexed keywords

CASPASE; CASPASE INHIBITOR; GANCICLOVIR; PROTEIN BCL 2; RECEPTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CELL KILLING; CLONOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUICIDE GENE;

ADENOVIRIDAE; AMINO ACID CHLOROMETHYL KETONES; ANTIVIRAL AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; COLONY-FORMING UNITS ASSAY; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME C GROUP; ENZYME ACTIVATION; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MEMBRANE GLYCOPROTEINS; NEUROBLASTOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TETRAZOLIUM SALTS; THIAZOLES; THYMIDINE KINASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036215245     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700448     Document Type: Article

References (52)

1. Apoptosis control by death and decoy receptors
2. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases
3. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis
4. Suicide gene therapy for pediatric tumors
5. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene
6. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
7. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
8. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
9. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
10. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability
11. Human pharmacokinetics of the antiviral drug DHPG
12. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
13. Pseudotyped retroviral vectors for studies of human gene therapy
14. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
15. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
16. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells
17. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
18. Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: Identification of apoptotic response
19. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells
20. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
21. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
22. Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines
23. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
24. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene
25. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
26. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
27. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma
28. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo
29. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis
30. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes
31. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells
32. Molecular biology of neuroblastoma
33. Apoptosis or necrosis for tumor immunotherapy: What's in a name?
34. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
35. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
36. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
37. Fas ligand-induced apoptosis
38. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
39. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
40. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
41. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha
42. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
43. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
44. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
45. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression
46. Cancer gene therapy: Hard lessons and new courses
47. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
48. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
49. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
50. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
51. Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase
52. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene